Real-World Outcomes

A new study compared all-cause health care costs and health resource utilization associated with first targeted therapies for advanced renal cell carcinoma.
Subjective assessment of solid tumor response to therapy may misinform the intended benefit and limit the potential role of real-world evidence in value-based care research.
William B Weeks, MD, PhD, MBA, discusses new data that show per-capita end-of-life spending is decreasing and contributing to overall per-capita Medicare spending growth moderation.
The results from a randomized controlled trial were compared with a real-world cohort for the safety and efficacy of a biosimilar to treat chemotherapy-induced neutropenia in patients with breast cancer.
A new study sought to better define real-world initiation, management, and outcomes of patients with chronic lymphocytic leukemia treated with a standard-of-care therapy.
Widespread use of alternative payment models may improve the quality of breast and colorectal cancer screening programs.
Socioeconomic inequalities may affect cancer-specific survival and overall survival in patients with squamous cell carcinoma of the anus.
A new study suggests the strength of evidence cited by the National Comprehensive Cancer Network to support recommendations deviating from FDA-approved therapy recommendations is not robust.
A National Cancer Database analysis revealed racial and ethnic disparities in patients with gastric cancer in the use of preoperative chemotherapy and in outcomes.
Despite significant treatment advancements in the management of multiple myeloma over the last 20 years, racial disparities in health care access and survival continue to exist.